Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia

Hematology

Volumn 19, Issue 1, 2014, Pages 22-30

  Shamaa, Sameh ^a   Laimon, Nabil ^a   Aladle, Doaa A ^a   Azmy, Emad ^a   Elghannam, Doaa M ^a   Salem, Dalia A ^a   Taalab, Mona M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Acute myeloid leukemia; AML; FLT3 ITD; NPM1; Prognosis

Indexed keywords

CYTARABINE; DOXORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FMS LIKE TYROSINE KINASE 3 INTERNAL TANDEM DUPLICATION GENE; FOLLOW UP; GEL ELECTROPHORESIS; GENE; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NUCLEOPHOSMIN 1 GENE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT RESPONSE;

ACUTE MYELOID LEUKEMIA; AML; FLT3-ITD; NPM1; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOGENETICS; DISEASE-FREE SURVIVAL; EGYPT; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TANDEM REPEAT SEQUENCES; YOUNG ADULT;

EID: 84893103274     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845413Y.0000000085     Document Type: Article

References (38)

1. Avivi I, Rowe JM. Prognostic factors in acute myeloid leukemia. Curr Opin Hematol. 2005;12:62-7.
2. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4:529-33.
3. Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell. 2004;5:465-75.
4. Lee SY, Park JH, Kim S, Park EJ, Yun Y, Kwon J. A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-Binding proteins in response to DNA double-strand breaks. Biochem J. 2005;388:7-15.
5. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107:4514-23.
6. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011-20.
7. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+AML): biologic and clinical features. Blood. 2007; 109:874-85.
8. Nakagawa M, Kameoka Y, Suzuki R. Nucleophosmin in acute myelogenous leukemia (letter). N Engl J Med. 2005;352: 1819-20.
9. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111:2776-84.
10. Rosnet O, Buhring HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996;10:238-48.
11. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-18.
12. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-42.
13. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-9.
14. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group. Blood. 2002;100:4372-80.
15. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-35.
16. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapyrelated acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18:120-5.
17. Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ, et al. Central review of cytogenetics necessary for cooperative group correlative and clinical studies of adult acute leukemia: the cancer and leukemia group B experience. Int J Oncol. 2008;33:239-44.
18. Greer J, Baer M, Kinnery M. Acute myelogenous leukemia. In: Lee G, Foester J, Leukens J, Pareskerva F, Greer J, Rogers G, (eds.) Wintrobe's clinical hematology. 12th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 2045-62.
19. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005; 106(8):2854-61.
20. Wang L, Lai W, Meng H, Qian W, Mai W, Tong H, et al. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics. Science 2010;11(10):762-70.
21. Haferlach T, Bacher U, Alpermann T, Haferlach C, Kern W, Schnittger S. Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype. Leuk Res. 2012;36(1):51-8.
22. Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-6.
23. Ghanem H, Tank N, Tabbara IA. Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics. Am J Hematol. 2012;87(1):69-77.
24. Kim Y, Kim H, Lee S, Ahn J, Yang D, Lee J, et al. Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol. 2010;45: 36-45.
25. Döhner K, Döhner H. Molecular characterization of acute myeloid leukemia. Hematologica. 2008;93(7):976-82.
26. de Jonge HJ, Huls G, de Bont ES. Gene expression profiling in acute myeloid leukaemia. Neth J Med. 2011;69(4):167-76.
27. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3): 254-66.
28. Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia. 2002;16(10):2027-36.
29. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood. 2005;105(12):4792-9.
30. Rocnik JL, Okabe R, Yu JC, Lee BH, Giese N, Schenkein DP, et al. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood. 2006;108(4): 1339-45.
31. Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S, et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia. 2008; 22:1234-40.
32. Scholl S, Fricke HJ, Sayer HG, Hoffken K. Clinical implications of molecular genetic aberrations in acute myeloid leukemia. J Cancer Res Clin Oncol. 2009;135:491-505.
33. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106(12):3733-9.
34. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005; 106(12):3747-54.
35. Brown P, McIntyre E, Rau R, Meshinchi S, Lacayo N, Dahl G, et al. The incidence and clinical significance of nucleo-phosmin mutations in childhood AML. Blood. 2007;110: 979-85.
36. Hollink IH, Zwaan CM, Zimmermann M, Arentsen-Peters TC, Pieters R, Cloos J, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2009;23: 262-70.
37. National Comprehensive Cancer Network. Version 2. 2010 (accessed 2010 Jan 8). Available at: http://www.nccn.org/professionals/physician_gls/PDF/aml.pdf
38. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21: 4642-9.